JPRN-UMIN000001214已完成2 期
Phase II study of Neoadjuvant Letrozole and Docetaxel for Postmenopausal, Endocrine-responsive and Anthracycline non-responsive Breast Cancer (JBCRG-05) - JBCRG-05
Japan Breast Cancer Research Group (JBCRG)0 个研究点目标入组 3 人开始时间: 2008年6月27日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 3
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 50years-old 至 70years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. Unmanageable serious complications 2. HCV 3. Unmanageable diabetes 4. Suspicious infection with fever 5. Active double cancer 6. Neuropathy 7. Edema 8. Inflammatory breast cancer 9. Bilateral breast cancer 10. History of drug-hypersensitivity 11. Under treatment of continuous systematic steroids, estrogen and raloxifene 12. Serious mental disease 13. Patient judged inappropriate for this study by the physicians
研究者
相似试验
已完成
2 期
Phase II study of Neoadjuvant Letrozole for Postmenopausal Women with Endocrine-responsive and Anthracycline non-responsive Breast Cancer (JBCRG-06)Postmenopausal, hormone-receptor positive and primary breast cancerJPRN-UMIN000001325Japan Breast Cancer Research Group (JBCRG)
已完成
2 期
Evaluation of efficacy of letrozole as a neoadjuvant endocrine therapy in postmenopausal patients with hormone receptor-positive breast cancerBreast cancerJPRN-UMIN000003101Tohoku University Graduate School of Medicine30
Unknown
2 期
Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal WomenER Positive, HER2 Negative Breast CancerNCT01709370Organisation for Oncology and Translational Research45
暂停
2 期
Study of neoadjuvant Letrozole combined with standerd chemotherapy for postmenopausal women with Endocrine-responsive Breast Cancer(subject of stage2,3A)Postmenopausal, hormone-receptor positive and resectable primary breast cancerJPRN-UMIN000002447iigata Cancer Center Hospital80
已完成
2 期
Phase II study of neoadjuvant and adjuvant docetaxel/cisplatin/5-fluorouracil in resectable esophagus canceresophagus cancerJPRN-UMIN000005588Jikei university of medicine department of surgery, department of oncology and hematology12